A. George Wilson
Researcher
Also affiliated: University of Kentucky (2015–2024); Medical University of South Carolina (2016); University of Georgia (2011–2015); Indiana University Bloomington (2011–2015); Carilion Clinic (2013–2015); Indiana University (2011); Villanova University (2011); Virginia Tech (2013–2015)
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
A. George Wilson's research program investigates the neurobiological and behavioral mechanisms underlying substance use and decision-making. His work has explored the role of vesicular monoamine transporter-2 (VMAT2) inhibitors, such as JPC-141, in preventing methamphetamine-induced dopamine toxicity and blocking methamphetamine self-administration in rat models. Wilson's publications also address choice behavior and delay discounting, with applications to understanding economic decision-making and substance abuse. He has authored 27 publications, which have been cited 1,397 times, and holds an h-index of 15. Wilson collaborates with researchers at the University of Arkansas for Medical Sciences, including Peter A. Crooks, Justin R. Nickell, Cassie M. Chandler, and John P. Culver.
Metrics
- h-index: 15
- Publications: 27
- Citations: 1,413
Selected Publications
-
Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats (2024)
Collaboration Network
Top Collaborators
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
Similar Researchers
Based on overlapping research topics